The abstract is read at the publisher; the summary is JClub's.
In adults with stage 2/3 autosomal dominant polycystic kidney disease, monthly lanreotide 120 mg did not slow mGFR decline over three years versus placebo.
- Why it matters: Somatostatin analogues shrink cysts, but prior randomized evidence has not consistently shown benefit for kidney function decline, leaving uncertainty about effects on GFR.
- What they did: In a randomized, double-blind, placebo-controlled trial, adults with measured GFR 30–89 ml/min/1.73 m² received monthly lanreotide 120 mg or 0.9% sodium chloride for up to three years; mGFR slope used iohexol clearance at baseline, weeks 72 and 144 with a linear mixed-effects model.
- The result: The primary between-arm annualized mGFR trajectory difference was -0.3 ml/min/1.73 m² per year (95% CI -3.4 to 2.8), and kidney events and quality-of-life were similar; gastrointestinal adverse events were more frequent and hypoglycemia occurred in 11.1% vs 1.4%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.